IC50: ~30 μM (K _ATP )

5-Hydroxydecanoate (5-HD) treatment abolishs the beneficial effects of penehyclidine hydrochloride (PHC) preconditioning in anoxia/reoxygenation (A/R)‐induced injury in H9c2 cells. 5-Hydroxydecanoate blocks the inhibitory effect of PHC on Ca ²⁺ overload and ROS production. 5-Hydroxydecanoate promotes the release of Cyt-C from mitochondria into cytoplasm. 5-Hydroxydecanoate attenuats the anti-apoptotic effect of PHC. PHC treatment shows remarkably decreases levels of Bax and cleaved caspase-3, and increases levels of Bcl-2. 5-Hydroxydecanoate pretreatment reverses the effects of PHC on their expression levels. 5-Hydroxydecanoate blocks the effects of PHC on K _ATP channels.

5-Hydroxydecanoate (100 μM) treatment abolishes the effects of ischemic preconditioning (IPC) on the contractile recovery and does not affect its effect on the contracture, lactate production, glycogenolysis and viable tissue in rats.